Pharmaceutical giant Pfizer sealed the deal in a blockbuster $150 billion merger with Irish-based drug maker Allergan. In one of the largest transactions in industry history, Botox maker Allergan will acquire Pfizer in a maneuver known as a reverse merger, which will allow the U.S. company to legally move abroad and lower its tax bill. The tie-up comes despite the Obama administration’s effort to thwart such mergers and the loss of corporate tax revenue.
Read it at The New York Times
